drugset / Trial / NCT00881179

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

NCT00881179

Phase 1 Completed 24 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Timeline

Start
2002-05
Primary completion
2002-06
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 250 mg

Indications

No indication recorded.